Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation

Cancer Letters

Volumn 296, Issue 2, 2010, Pages 178-185

  Sun, Bo ^a   Yu, Kyung Rok ^a   Bhandari, Dilli Ram ^a   Jung, Ji Won ^a   Kang, Soo Kyung ^a   Kang, Kyung Sun ^a  

^a Seoul National University   (South Korea)

Author keywords

Breast cancer; Extracellular matrix; Human umbilical cord blood; Mesenchymal stem cells; PTEN

Indexed keywords

DICKKOPF 1 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STEM CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; UMBILICAL CORD BLOOD; UPREGULATION;

ADULT; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL DIVISION; EXTRACELLULAR MATRIX; FEMALE; FETAL BLOOD; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESENCHYMAL STEM CELLS; MITOMYCIN; NEOPLASM METASTASIS; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 77955281514     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.04.007     Document Type: Article

References (33)

1. Hoek K., Rimm D.L., Williams K.R., Zhao H., Ariyan S., Lin A., Kluger H.M., Berger A.J., Cheng E., Trombetta E.S., Wu T., Niinobe M., Yoshikawa K., Hannigan G.E., Halaban R. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 2004, 64:5270-5282.
2. Monk M., Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene 2001, 20:7.
3. Lotem J., Sachs L. Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 2006, 25:7663-7672.
4. Ivanova N.B., Dimos J.T., Schaniel C., Hackney J.A., Moore K.A., Lemischka I.R. A stem cell molecular signature. Science 2002, 298:601-604.
5. Boyer L.A., Lee T.I., Cole M.F., Johnstone S.E., Levine S.S., Zucker J.P., Guenther M.G., Kumar R.M., Murray H.L., Jenner R.G., Gifford D.K., Melton D.A., Jaenisch R., Young R.A. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122:947-956.
6. Hendrix M.J.C., Seftor E.A., Seftor R.E.B., Kasemeier-Kulesa J., Kulesa P.M., Postovit L.-M. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 2007, 7:246-255.
7. Kulesa P.M., Kasemeier-Kulesa J.C., Teddy J.M., Margaryan N.V., Seftor E.A., Seftor R.E.B., Hendrix M.J.C. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc. Natl Acad. Sci. USA 2006, 103:3752-3757.
8. 2). Apoptosis 2006, 11:1617-1628.
9. Pierce G.B., Pantazis C.G., Caldwell J.E., Wells R.S. Specificity of the control of tumor formation by the blastocyst. Cancer Res. 1982, 42:1082-1087.
10. Mariana Gerschenson, Kathy Graves, Carson Steven D., Wells Robert S., Barry P.G. Regulation of melanoma by the embryonic skin. Proc. Natl Acad. Sci. USA 1986, 83:7307-7310.
11. Illmensee K., Mintz B. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc. Natl Acad. Sci. USA 1976, 73:549-553.
12. Postovit L.-M., Seftor E.A., Seftor R.E.B., Hendrix M.J.C. A three-dimensional model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells 2006, 24:501-505.
13. Postovit L.-M., Margaryan N.V., Seftor E.A., Kirschmann D.A., Lipavsky A., Wheaton W.W., Abbott D.E., Seftor R.E.B., Hendrix M.J.C. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc. Natl Acad. Sci. 2008, 105:4329-4334.
14. Khakoo A.Y., Pati S., Anderson S.A., Reid W., Elshal M.F., Rovira I.I., Nguyen A.T., Malide D., Combs C.A., Hall G., Zhang J., Raffeld M., Rogers T.B., Stetler-Stevenson W., Frank J.A., Reitz M., Finkel T. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 2006, 203:1235-1247.
15. Zhu Y., Sun Z., Han Q., Liao L., Wang J., Bian C., Li J., Yan X., Liu Y., Shao C., Zhao R.C. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009, 23:925-933.
16. Qiao L., Xu Z.-l., Zhao T.-j., Ye L.-h., Zhang X.-d. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett. 2008, 269:67-77.
17. Sun B., Roh K.-H., Park J.-R., Lee S.-R., Park S.-B., Jung J.-W., Kang S.-K., Lee Y.-S., Kang K.-S. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy 2009, 11:289-298.
18. Amatangelo M.D., Bassi D.E., Klein-Szanto A.J.P., Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol. 2005, 167:475-488.
19. Glennie S., Soeiro I., Dyson P.J., Lam E.W.-F., Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
20. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24:74-85.
21. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
22. Jiang Z., Pore N., Cerniglia G.J., Mick R., Georgescu M.-M., Bernhard E.J., Hahn S.M., Gupta A.K., Maity A. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 2007, 67:4467-4473.
23. Frattini M., Saletti P., Romagnani E., Martin V., Molinari F., Ghisletta M., Camponovo A., Etienne L.L., Cavalli F., Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 2007, 97:1139-1145.
24. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
25. Perez-Tenorio G., Stal O. Activation of AKT//PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 2002, 86:540-545.
26. Fournier M.V., Fata J.E., Martin K.J., Yaswen P., Bissell M.J. Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells. Cancer Res. 2009, 69:4545-4552.
27. Li Z., Wang L., Zhang W., Fu Y., Zhao H., Hu Y., Prins B.P., Zha X. Restoring E-cadherin-mediated cell-cell adhesion increases PTEN protein level and stability in human breast carcinoma cells. Biochem. Biophys. Res. Commun. 2007, 363:165-170.
28. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8:179-183.
29. Nardella C., Carracedo A., Alimonti A., Hobbs R.M., Clohessy J.G., Chen Z., Egia A., Fornari A., Fiorentino M., Loda M., Kozma S.C., Thomas G., Cordon-Cardo C., Pandolfi P.P. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci. Signal. 2009, 2:ra2.
30. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br. J. Cancer 2005, 94:195-199.
31. Polakis P. Wnt signaling and cancer. Gen. Dev. 2000, 14:15.
32. Fodde R., Brabletz T. Wnt/[beta]-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007, 19:150-158.
33. Schlange T., Matsuda Y., Lienhard S., Huber A., Hynes N. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 2007, 9:R63.